Product Name: Raloxifene Hydrochloride Powder
CAS #: 82640-04-8
Raloxifene Hydrochloride Price: According to your needs
Raloxifene Hydrochloride Half Life: 27 hours
Raloxifene Hydrochloride Dosage: 60 mg orally per day
Raloxifene Hydrochloride Detection time: Currently unknown
Raloxifene Hydrochloride Side Effect: Coughing blood;headache or migraine headache;loss of or change in speech, coordination, or vision;pain or numbness in chest, arm, or leg shortness of breath
Raloxifene Hydrochloride Results: For treatment or prevention of osteoporosis, advise patients to add supplemental calcium and/or vitamin D if daily intake is inadequate;When this drug is used to reduce the risk of invasive breast cancer, the optimum duration of treatment is not known.
Raloxifene Hydrochloride Specifications:
|Appearance||White &off-white powder||Conform|
|Solubility||Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water||Conform|
|Tests||Loss on drying||≤0.5%||0.4%|
|Residue on ignition||≤0.1%||0.06%|
|RRelated substances||Raloxifene Impurity1||≤0.20 %||0.10%|
|Any unspecified individual impurity 2||≤0.10%||Max. 0.08%|
Raloxifene Hydrochloride Descriptions:
EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.
The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1- piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S•HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an offwhite to pale-yellow solid that is very slightly soluble in water.
EVISTA is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.
Raloxifene Hydrochloride Effects:
-Treatment and prevention of osteoporosis in postmenopausal women.
-Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and/or at high risk of invasive breast cancer.